AzTrials
AzTrials

Hyperglycemia, PostprandialNCT05140629

Effect of Baobab Fruit on Postprandial Glycaemia in Healthy Adults

A study testing Baobab fruit aqueous extract in people with Hyperglycemia, Postprandial, run by Egas Moniz - Cooperativa de Ensino Superior, CRL at 1 site in Portugal.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Baobab fruits have been traditionally used in Africa due to its therapeutic proprieties attributed to it high polyphenol content. The aim of the study was to investigate the effect of baobab fruit on postprandial glycaemia on healthy adults and to measure its bioactive compounds and antioxidant activity. Read more about this study

Who is it for?
Ages 18 to 40 yearsHealthy volunteers can take part
Conditions the study is for
Hyperglycemia, Postprandial
What is being tested?
Baobab fruit aqueous extract
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
31 participants
Where
1 sitePortugal
Study dates
2 Jan 2017to 30 Oct 2018
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 40 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Not currently undergoing lactation or pregnancy,
  • To be able to read and sign the informed consent.
  • Healthy subjects and a fasting blood glucose < 126 mg/dl

Who cannot join

  • Subjects that were less than 8 or more than 10 hours fasting,
  • To have symptoms and history of gastrointestinal, hepatic and cardiovascular diseases
  • Baobab intolerance or allergy,
  • Drug and/or supplement consumption capable of influencing plasma glucose
  • Have ingested baobab, water, coffee or alcohol intake and smoked tobacco consumption within 8 hours before the intervention

Trial locations and contacts

1 site in 1 country.

Portugal1 site
  • Instituto Universitário Egas Moniz

    Almada, Monte de Caparica, 2829-511

Other trials in Portugal

About this study

Official title: Adansonia Digitata L. (Baobab Fruit) Effect on Postprandial Glycaemia in Healthy Adults: a Randomized Controlled Trial

Baobab fruits have been traditionally used in Africa due to its therapeutic proprieties attributed to it high polyphenol content. The aim of the study was to investigate the effect of baobab fruit on postprandial glycaemia on healthy adults and to measure its bioactive compounds and antioxidant activity. The study was conducted on 31 healthy subjects. The participants were randomly allocated in control group (oral glucose tolerance test (OGTT); n = 16) and in intervention group (OGTT followed by administration of 250 ml baobab aqueous extract (BAE); n = 15). Total phenols, proanthocyanidins, hydrolysable tannins and antioxidant activity (FRAP, DPPH, ABTS and inhibition of O2•- and NO• methods) were quantified. Repeated Measures ANOVA of mixed type and Independent samples t-test were used.

Read the detailed description

This study was approved by Egas Moniz Cooperativa de Ensino Superior Ethics Committee (protocol code 518) and was carried out in accordance with the Declaration of Helsinki (Declaration of 1975, revised in 2000). An informed consent was given to all eligible participants, after oral and written information about the study.

This randomized controlled clinical trial, blind to subjects, was conducted with 31 subjects, recruited at the Campus Universitário Egas Moniz, in Monte de Caparica, Portugal. After eligibility criteria and inform consent signed, participants were subjected to the inclusion and exclusion criteria and subsequently randomly allocated in to control or intervention groups. The method of allocation sequence was based on sequentially numbers. The first patient was randomly assigned to intervention or control group, and the following patients were sequentially allocated alternately to each group. A codification was attributed to each participant in order to maintained anonymity and ensure confidentiality of data.

After a period of 8-10 hours fasting, the control group was given OGTT and the intervention group was given OGTT followed by baobab aqueous extract.

Baobab aqueous extract preparation:

The baobab fruit was bought in the market of Benfica, located in the city of Luanda (Angola) and brought to Lisbon (Portugal) duly packed in a plastic bag and stored in a dried environmental local until needed. For the aqueous extraction of the fruit 40 ± 1 g of pulp, seeds and red filaments were weighed and the fruit was boiled in 300 ml of water for 5 minutes. After slowly cooling until room temperature, extract was then placed in a refrigerator in a container where it remained for 8 hours at an average temperature of 10°C. The BAE was sieved with the aid of a net sieve, separating it from the seeds and filaments, and was subsequently subjected to the clinical trial and the antioxidant assays. For the antioxidant assays, after filtration, the extract was passed through the blender (Kenwood Multipro Compact Food Processor FDP302SI), filtered again obtaining homogeneous samples, avoiding the formation of precipitates during the analysis. Final concentration of the aqueous extract obtained, for both clinical trial and chemical analysis, was 0.1333 g Adansonia digitata L. (AD) / ml extract fresh weight (FW).

Interventions:

After overnight fasting, blood glucose level was assessed through a capillary drop blood, immediately before Oral Glucose Tolerance Test (t0). The control group participants ingested glucose solution alone (OGTT) prepared with 75 g of anhydrous oral glucose as prescribed by the American Dietetic Association (ADA), dissolved in 200 ml of water. The intervention group ingested glucose solution followed by 250 ml of baobab aqueous extract (33.33 g FW). Blood glucose level was also measured at 30 (t30), 60 (t60), 90 (t90) and 120 (t120) minutes immediately after intervention, for each participant, in control and intervention groups. Glucometer equipment, strips for glucose meters (One Touch Select Plus) and sterilized lancets (Sarstedt normal 21G) were used to measure blood glucose concentrations, taking due care of safety and asepsis. Based on the glycaemia values, the blood glucose incremental area under the curve (AUCi) of each participant was defined using the GraphPad Prism program (version 5.0). Maximum concentrations (Cmax) and variations of maximum concentrations (ΔCmax) were determined by comparing them with their respective baseline glycemia levels values.

Anthropometric parameters assessment:

The anthropometric parameters were also collected, namely, weight, height and body mass index (BMI). The BMI was calculated as weight (Kg) divided by height (m2) squared (Kg/m2). Body weight was estimated by bio-impedance, through scale the Inbody®, model 230.

Dietary ingestion assessment:

Participants of the study completed a 24-hour food recall questionnaire, which were carefully instructed by an investigator to identify all food consumed. The amount of each food ingested was estimated with help from pictures. A book with pictures of meals in different sizes was used. The investigator reviewed the questionnaire together with the participant. Food intake of each participant was analysed using the software The Food Processor SQL (version 11.3.285) obtaining total energy, carbohydrates, proteins and lipids mean intake.

Total phenol, proanthocyanidins and hydrolysable tannins content assessment:

Total phenolic concentration was determined according to the Folin Ciocalteu method employing gallic acid as standard. Results were expressed as mg of gallic acid equivalents/L (GAE/L). For this analysis, 125 μl of BAE, previously diluted (x15) in water and 125 μl of ethanol was added to 2.5 ml of Folin-Ciocalteu reagent solution (1:10 diluted in H2O) and 2 ml of aqueous sodium carbonate (Na2CO3) 1M. After 15 minutes the absorbance was measured at 765 nm.

The content of proanthocyanidins was determined according to Gu et al (2002) method with modifications, which is based on acidic hydrolysis of proanthocyanidins polymers producing reddish pigments in hot 1-butanol/ hydrochloric acid solution. It was added 200 μl of BAE diluted (x2) to 200 μl of methanol and 2600 μl of HCl /1-butanol 10%(v/v) solution. The test tubes were shaken and incubated, at 100°C for 50 minutes. The absorbance was measured at 550 nm. Results are expressed as mg equivalents of proanthocyanidins A2 /L (EPA2/L).

The method of Willis and Allen was adapted for the determination of hydrolysable tannins of the BAE. A volume of 1 ml of extract was added to 5 ml of 2.5% potassium iodate (KIO3). The mixture was then stirred and returned to the water bath at 25°C for 20 minutes. Absorbance reading was performed by a spectrophotometer at 550 nm and the results were expressed as mg of tannic acid equivalents/L (TAE/L).

Antioxidant assays:

Ferric Reducing Antioxidant Power (FRAP) method: the antioxidant effect (reducing ability) was evaluated by monitoring the formation of an intense blue color from the Fe2+ TPTZ complex, according to the Ferric Reducing Antioxidant Power (FRAP) assay. A volume of 2850µl (25ml 300mM acetate buffer pH=3,6 solution plus 2,5 ml 10mM TPTZ solution in HCl 40mM + 2,5 ml 20mM FeCl3.6H2O solution) was added to 150µl of diluted BAE.. The tubes were kept in the dark for 30 minutes (7 assays at different concentrations). The absorbance was determined at 593 nm and the results were expressed in mg of Trolox equivalents/L (TE/L).

ABTS method: this method was based on the capacity of a sample to inhibit the ABTS radical (ABTS+) compared with a reference antioxidant standard (Trolox). The ABTS+ radical was generated by chemical reaction with potassium persulfate (K2S2O8). Thus, 25 ml of ABTS (7 mM) was added to 440 µl of K2S2O8 (140 mM) and allowed to stand in darkness at room temperature for 12-16 h. The solution was prepared by taking a volume of the previous solution and diluting it in ethanol until its absorbance at λ = 734 nm was 0.70. The tubes were kept in the dark for 30 minutes. The results expressed in mg of Trolox equivalents/L (TE/L).

The DPPH method: this method was determined by the 2,2-diphenyl-1-picrylhydrazyl radical scavenger. A volume of 150 μl BAE was added to 2850 μl of DPPH solution previously prepared in methanol with a λ=515 nm of 1.1. The solutions were kept for 24 hours in the absence of light. The absorbance was determined at 515 nm and the results expressed in mg of Trolox equivalents/L (TE/L).

Inhibition capacity of O2•- anion and NO radical:

The superoxide anion is generated by oxidation of NADH by reacting with PMS and oxygen, causing the reduction of NBT. A volume of 500 μl of BAE with different concentration were added to 2 ml of NADH (189μM) and NBT (120 μM) in 40 mM Tris-HCl buffer pH 8. The reaction was started after the addition of 0.5 ml of PMS (60 μM) and after 5 minutes incubation at room temperature, the absorbance was measured at 560 nm.

The inhibition NO radical test was based on the method of Nikkhah and coworkers (2008). A volume of 250 μl of BAE with different concentrations was added to 1 ml of sodium nitroprusside and 250 μl of phosphate buffered saline (PBS). The mixture was kept for 150 minutes at 25°C. Then, 0.5 ml of this mixture was added to 1 ml of sulfanilic acid (0.33% in 20% glacial acetic acid), and kept for 5 minutes at room temperature. Then it was added 1 ml of NED (0.1% w/v) and kept this mixture for 30 minutes at 25°C. At the end of the reaction a pink chromophore was formed. The absorbance was measured at 540 nm. The percentage of inhibition of O2•- and NO radicals was determined using equation 1 and the results were expressed as mg of gallic acid equivalents (GAE)/L.

Statistical analysis:

Statistical analysis was performed using the Excel® and SPSS® (Statistical Package for Social Sciences) version 27.0 software for Mac. Data are presented as mean ± SD (standard deviation) and SEM (standard error of the mean). Repeated measurement ANOVA of mixed type was used to assess the difference between the 2 groups for postprandial blood glucose at different times. The independent samples t-test was used to assess the difference between the 2 groups for anthropometric parameters, total energy intake, carbohydrates, protein and lipid, Cmax, ΔCmax and AUCi values. All statistical tests were performed at the 5% level of significance.

Being tested
Baobab fruit aqueous extract, Placebo OGTT
Keywords
Adansonia digitata, Baobab fruit, Postprandial glycaemia, Antioxidant, Polyphenols, Proanthocyanidins
Medical subject headings
Hyperglycemia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Baobab fruit aqueous extractOther

    After overnight fasting, blood glucose level was assessed through a capillary drop blood, immediately before Oral Glucose Tolerance Test (t0). The intervention group ingested glucose solution followed by 250 ml of baobab aqueous extract (33.33 g FW). Blood glucose level was also measured at 30 (t30), 60 (t60), 90 (t90) and 120 (t120) minutes immediately after intervention, for each participant, in control and intervention groups. Glucometer equipment, strips for glucose meters (One Touch Select Plus) and sterilized lancets (Sarstedt normal 21G) were used to measure blood glucose concentrations, taking due care of safety and asepsis.

  • Placebo OGTTOther

    After overnight fasting, blood glucose level was assessed through a capillary drop blood, immediately before Oral Glucose Tolerance Test (t0). The control group participants ingested glucose solution alone (OGTT) prepared with 75 g of anhydrous oral glucose as prescribed by the ADA, dissolved in 200 ml of water. Blood glucose level was also measured at 30 (t30), 60 (t60), 90 (t90) and 120 (t120) minutes immediately after intervention, for each participant, in control and intervention groups. Glucometer equipment, strips for glucose meters (One Touch Select Plus) and sterilized lancets (Sarstedt normal 21G) were used to measure blood glucose concentrations, taking due care of safety and asepsis.

Study groups in NCT05140629
Study groupRoleWhat they receive
Placebo (OGTT)Placebo comparatorThe control group participants ingested glucose solution alone (OGTT) prepared with 75 g of anhydrous oral glucose as prescribed by the ADA, dissolved in 200 ml of water.
Receives: Other: Placebo OGTT
Intervention (OGTT plus Baobab fruit extract)ExperimentalThe intervention group ingested glucose solution followed by 250 ml of baobab aqueous extract (33.33 g FW).
Receives: Other: Baobab fruit aqueous extract

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Postprandial blood glucose levels time curve

    Mean blood glucose levels (mmol/L) obtained after oral glucose tolerance test in control group and after oral glucose tolerance test plus baobab extract in intervention group at different moments

    Measured: Before intervention and after 30, 60, 90, and 120 minutes after intervention

  2. Incremental area under the curve of glucose levels

    the blood glucose incremental area under the curve (AUCi) of each participant was defined using the GraphPad Prism program (version 5.0).

    Measured: At 120 minutes after intervention

  3. Blood glucose maximum concentrations

    Mean blood glucose levels (mmol/L)

    Measured: At 120 minutes after intervention

Secondary outcomes (15)
  1. Weight of participants

    Mean values of weight (in kilograms)

    Measured: At baseline

  2. Body mass index of participants

    Mean values of body mass index (Kg/m2), calculated as weight (Kg) divided by height (m2) squared (Kg/m2)

    Measured: At baseline

  3. Height of participants

    Mean values of height (in meters)

    Measured: At baseline

  4. Total energy intake intake of participants

    Mean values of total energy intake (in kilocalorie - Kcal), obtained through The Food Processor SQL software

    Measured: At the day before intervention

  5. Total protein intake of participants

    Total protein intake (in grams - g), obtained through The Food Processor SQL software

    Measured: At the day before intervention

  6. Total carbohydrate intake of participants

    Total carbohydrate intake (in grams - g), obtained through The Food Processor SQL software

    Measured: At the day before intervention

  7. Total lipid intake of participants

    Total lipid intake (in grams - g), obtained through The Food Processor SQL software

    Measured: At the day before intervention

  8. Total phenols content determination

    Mean values of total phenols (expressed as mg of gallic acid equivalents/L - GAE/L)

    Measured: At baseline

  9. Proanthocyanidins content determination

    Mean values of proanthocyanidins (expressed as mg equivalents of procyanidin A2 /L - EPA2/L)

    Measured: At baseline

  10. Hydrolysable tannins content determination

    Mean values of hydrolysable tannins (expressed as mg of tannic acid equivalents/L - TAE/L)

    Measured: At baseline

  11. DPPH radical scavenger capacity

    Mean values of antioxidant capacity by DPPH (2,2-diphenyl-1-picrylhydrazyl) radical scavenger (expressed in mg of Trolox equivalents/L - TE/L)

    Measured: At baseline

  12. Ferric Reducing Antioxidant Power (FRAP) determination

    Mean values of antioxidant capacity by FRAP test (expressed in mg of Trolox equivalents/L - TE/L).

    Measured: At baseline

  13. ABTS radical (ABTS+) inhibition capacity

    Mean values of ABTS inhibition capacity (expressed in mg of Trolox equivalents/L - TE/L).

    Measured: At baseline

  14. Superoxide radical inhibition capacity

    Percentage of superoxide radical inhibition capacity (expressed as %)

    Measured: At baseline

  15. Nitric oxide inhibition capacity

    Percentage of nitric oxide radical inhibition capacity (expressed as %)

    Measured: At baseline

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 Dec 2021
  2. Study start2 Jan 2017
  3. Primary completion30 Jul 2018
  4. Study completion30 Oct 2018

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
31 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05140629
Sponsor's protocol ID
518baobab
Status last verified
Nov 2021
First submitted
5 Nov 2021
Last updated
1 Dec 2021
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing Baobab fruit aqueous extract in people with Hyperglycemia, Postprandial, run by Egas Moniz - Cooperativa de Ensino Superior, CRL at 1 site in Portugal.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 1 Dec 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Portugal. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Postprandial blood glucose levels time curve (time frame: Before intervention and after 30, 60, 90, and 120 minutes after intervention). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Dec 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in